/Companies

Belenos Biosciences

New York, US · Founded 2024 · 1 known investors

Find your way into Belenos Biosciences

Sign up to find every way you can get introduced to Belenos Biosciences

  • Your email: who you already know at Belenos Biosciences, and who your contacts know
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Belenos Biosciences team
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Belenos Biosciences develops long-acting bispecific antibody therapeutics for chronic inflammatory diseases such as COPD, asthma, atopic dermatitis, CRSwNP, and CSU. Its pipeline includes BEL512 (targeting TSLP and IL-13) and BEL536 (targeting OX40L and IL-13), both aimed at modulating type 2 inflammation.

Founders & leadership

DMDonnie McGrath
Donnie McGrathCEO & Co-Founder
MDMegan Dow
Megan DowCOO & Co-Founder
TDTania Dimitrova
Tania DimitrovaCFO & Co-Founder
GRGlenn Rosen
Glenn RosenChief Translational Officer & Co-Founder
DMDonnie McGrath, M.D., M.P.H.
Donnie McGrath, M.D., M.P.H.CEO & Co-FounderA physician-executive who has worked across drug development, corporate strategy, and business development, he served as Chief Corporate Strategy and Business Development officer at Biohaven and as CEO and later President and Executive Chairman of its China-focused affiliate BioShin. Earlier, he spent nearly a decade at Bristol-Myers Squibb in roles including development lead and Global Head of Virology and Neuroscience Search and Evaluation, and he has been a venture partner at OrbiMed since 2023.
MD
Megan Dow, Ph.D.COO & Co-Founder
TD
Tania Dimitrova, M.B.ACFO & Co-Founder
SD
StJohn Donnie McGrathExecutive

Board

BC
Bo ChenBoard director
CGCarl Gordon
Carl GordonBoard directorManaging Partner at OrbiMed
DWDavid Wang
David WangBoard directorPartner at OrbiMed

Investors · 1

Reported raises · per SEC filings

Form D private placements

$48M disclosed across 1 round · 2024

▶$48MraisedJul 2024 · 2 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Bo ChenDirector
  • Carl GordonDirector
  • Tania DimitrovaExecutive Officer
  • David WangDirector
  • Megan DowExecutive Officer
  • StJohn Donnie McGrathExecutive Officer, Director
Offering amount
$55M
Amount sold
$48M
First sale
Jul 2024
Incorporated
Corporation, Delaware, 2024
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Frequently asked questions

What does Belenos Biosciences do?
Belenos Biosciences develops long-acting bispecific antibody therapeutics for chronic inflammatory diseases such as COPD, asthma, atopic dermatitis, CRSwNP, and CSU. Its pipeline includes BEL512 (targeting TSLP and IL-13) and BEL536 (targeting OX40L and IL-13), both aimed at modulating type 2 inflammation.
Who founded Belenos Biosciences?
Belenos Biosciences was founded by Donnie McGrath, Megan Dow, Tania Dimitrova, Glenn Rosen, Donnie McGrath, M.D., M.P.H., Megan Dow, Ph.D., Tania Dimitrova, M.B.A in 2024.
Who are Belenos Biosciences's investors?
Belenos Biosciences's investors include OrbiMed.
How much funding has Belenos Biosciences raised?
Belenos Biosciences has disclosed $48M raised across 1 round.
Where is Belenos Biosciences headquartered?
Belenos Biosciences is headquartered in New York, US.